Education
About Us
Working with TipRanks
Follow Us
ESSA Pharma Inc (EPIX)
NASDAQ:EPIX
EPIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.40 - $8.59
Previous CloseN/A
Volume26.72K
Average Volume (3M)93.86K
Market Cap
$70.13M
Enterprise Value$142.43M
Total Cash (Recent Filing)$21.69M
Total Debt (Recent Filing)$7.49M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
May 13, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding44,388,550
10 Day Avg. Volume88,991
30 Day Avg. Volume93,865
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap2.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.39
Forecast
1Y Price Target
$2.25Price Target Upside42.41% Upside
Rating ConsensusHold
Number of Analyst Covering0
---
ESSA Pharma News
PremiumCompany Announcements
ESSA Pharma Inc. Explores Strategic Options Amid Losses
PremiumCompany Announcements
ESSA Pharma Reports Q1 Loss, Explores Strategic Options
PremiumCompany Announcements
ESSA Pharma Inc. Reports Strategic Shift Amid Losses---
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityEPIX's last reported cash balance of $126.8M offers flexibility to evaluate opportunities.
Oncology ExpertiseThe team's established record in oncology drug development may facilitate discussions around outside development candidates in that category.
Strategic OpportunitiesThe company will move to a strategic process in which it will explore options that maximize shareholder value.
Bears Say
Clinical Trial TerminationAll remaining clinical studies involving masofaniten, including those combining it with abiraterone acetate and apalutamide and other investigator-sponsored trials, will be discontinued.
Drug Development DiscontinuationEPIX announced that it will discontinue all masofaniten development following a pre-specified futility analysis that showed that this candidate failed to meet the target efficacy profile in the Phase 2 enzalutamide combo study in mCRPC patients naïve to second-generation antiandrogens.
Efficacy AnalysisThe futility analysis revealed that the enzalutamide monotherapy control arm was performing better than historical controls and similar to the masofaniten + enzalutamide combo.
---
Ownership Overview
2.17% Insiders
0.06% Mutual Funds
59.91% Other Institutional Investors
37.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
EPIX FAQ
What was ESSA Pharma Inc’s price range in the past 12 months?
ESSA Pharma Inc lowest stock price was $1.40 and its highest was $8.59 in the past 12 months.
What is ESSA Pharma Inc’s market cap?
ESSA Pharma Inc’s market cap is $70.13M.
When is ESSA Pharma Inc’s upcoming earnings report date?
ESSA Pharma Inc’s upcoming earnings report date is May 13, 2025 which is in 39 days.
How were ESSA Pharma Inc’s earnings last quarter?
ESSA Pharma Inc released its earnings results on Feb 11, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.18 by -$0.01.
Is ESSA Pharma Inc overvalued?
According to Wall Street analysts ESSA Pharma Inc’s price is currently Undervalued.
Does ESSA Pharma Inc pay dividends?
ESSA Pharma Inc does not currently pay dividends.
What is ESSA Pharma Inc’s EPS estimate?
ESSA Pharma Inc’s EPS estimate is -0.19.
How many shares outstanding does ESSA Pharma Inc have?
ESSA Pharma Inc has 44,388,550 shares outstanding.
What happened to ESSA Pharma Inc’s price movement after its last earnings report?
ESSA Pharma Inc reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.18. Following the earnings report the stock price went down -3.012%.
Which hedge fund is a major shareholder of ESSA Pharma Inc?
Currently, no hedge funds are holding shares in EPIX
---
ESSA Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.25 (42.41% Upside)
$2.25 (42.41% Upside)
Blogger Sentiment
Bullish
EPIX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 4.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.25%
12-Months-Change
Fundamentals
Return on Equity
-23.98%
Trailing 12-Months
Asset Growth
-15.13%
Trailing 12-Months
Company Description
ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
---
EPIX Stock 12 Month Forecast
Average Price Target
$2.25
▲(42.41% Upside)
Technical Analysis
Exelixis
―
Madrigal Pharmaceuticals
―
Karyopharm Therapeutics
―
Arvinas Holding Company
―
Biohaven Ltd.
―
---